• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Peri-transplant Stem Cell Kinetics After Daratumumab-Based Induction in Patients with Multiple Myeloma: Response to Mishra et al.

作者信息

Jain Ankur

机构信息

Department of Hematology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, 110029 India.

出版信息

Indian J Hematol Blood Transfus. 2020 Oct;36(4):763-765. doi: 10.1007/s12288-020-01273-0. Epub 2020 Mar 17.

DOI:10.1007/s12288-020-01273-0
PMID:33100725
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7573003/
Abstract
摘要

相似文献

1
Peri-transplant Stem Cell Kinetics After Daratumumab-Based Induction in Patients with Multiple Myeloma: Response to Mishra et al.达雷妥尤单抗诱导治疗的多发性骨髓瘤患者移植后干细胞动力学：对米什拉等人研究的回应
Indian J Hematol Blood Transfus. 2020 Oct;36(4):763-765. doi: 10.1007/s12288-020-01273-0. Epub 2020 Mar 17.
2
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.EMA 审查达雷妥尤单抗（Darzalex）治疗新诊断为多发性骨髓瘤的成年患者。
Oncologist. 2020 Dec;25(12):1067-1074. doi: 10.1002/onco.13554. Epub 2020 Oct 16.
3
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
4
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
5
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
6
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
7
[Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].[达雷妥尤单抗用于新诊断多发性骨髓瘤自体造血干细胞移植后的维持治疗]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1016-1021. doi: 10.3760/cma.j.issn.0253-2727.2023.12.008.
8
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.来那度胺联合地塞米松添加达雷妥尤单抗或硼替佐米治疗新诊断多发性骨髓瘤的成本效果分析。
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
9
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.达雷妥尤单抗用于骨髓瘤诱导治疗时与干细胞动员受损及移植后血液学恢复延长相关。
Cancers (Basel). 2024 May 13;16(10):1854. doi: 10.3390/cancers16101854.
10
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.达雷妥尤单抗、环磷酰胺、硼替佐米和地塞米松治疗多发性骨髓瘤：LYRA 研究的最终结果。
Leuk Lymphoma. 2022 Oct;63(10):2383-2392. doi: 10.1080/10428194.2022.2076847. Epub 2022 Jun 22.

引用本文的文献

1
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review.抗CD38单克隆抗体疗法对多发性骨髓瘤患者CD34+造血干细胞动员、采集及植入的影响——一项系统评价
Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944.

本文引用的文献

1
Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.在接受达雷妥尤单抗作为其多发性骨髓瘤首次诱导治疗方案一部分的患者中，中性粒细胞植入延迟。
Am J Hematol. 2020 Jan;95(1):E8-E10. doi: 10.1002/ajh.25654. Epub 2019 Oct 21.
2
Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者接受基于达雷妥尤单抗的联合化疗后动员不佳
Indian J Hematol Blood Transfus. 2019 Jul;35(3):584-586. doi: 10.1007/s12288-019-01135-4. Epub 2019 May 10.
3
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
4
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.达雷妥尤单抗、硼替佐米、环磷酰胺和地塞米松治疗新诊断和复发多发性骨髓瘤的 LYRA 研究。
Br J Haematol. 2019 May;185(3):492-502. doi: 10.1111/bjh.15806. Epub 2019 Mar 3.
5
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.达雷妥尤单抗联合治疗多发性骨髓瘤患者的药代动力学和暴露-反应分析。
Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.
6
Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth.达雷妥尤单抗在体外可与骨髓瘤患者动员的CD34+细胞结合，且无细胞毒性或祖细胞生长受损。
Exp Hematol Oncol. 2018 Oct 16;7:27. doi: 10.1186/s40164-018-0119-4. eCollection 2018.
7
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.对于达雷妥尤单抗难治性多发性骨髓瘤患者，添加免疫调节药物（IMiDs）可克服对这两种药物的难治性。
Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22.
8
Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment.骨髓间充质干细胞改善造血功能的研究：体外与体内模型。第 2 部分：对骨髓微环境的影响。
PLoS One. 2011;6(10):e26241. doi: 10.1371/journal.pone.0026241. Epub 2011 Oct 20.
9
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.移植的 CD34(+) 细胞剂量与非霍奇金淋巴瘤或多发性骨髓瘤患者自体外周血造血干细胞移植后血小板计数的长期恢复有关。
Biol Blood Marrow Transplant. 2011 Aug;17(8):1146-53. doi: 10.1016/j.bbmt.2010.11.021. Epub 2010 Nov 30.
10
Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.G-CSF 和培洛昔康与 G-CSF 和环磷酰胺相比用于自体造血干细胞动员的成本和临床分析。
Biol Blood Marrow Transplant. 2011 May;17(5):729-36. doi: 10.1016/j.bbmt.2010.08.018. Epub 2010 Oct 14.